# Trump's Drugmaker Investments Spark Democratic Criticism

> Democrats report Trump's stock portfolio grew by $56.2m in pharma firms benefiting from Medicare exemptions.
- Title: Trump's Drugmaker Investments Spark Democratic Criticism
- Summary: Democrats report Trump's stock portfolio grew by $56.2m in pharma firms benefiting from Medicare exemptions. Trump's stock holdings in drugmakers that avoid…
- Keywords: trump, medicare, drugmakers, stock portfolio, congressional democrats, pharmaceutical companies, medicare exemptions, president, white house, stock market, news, local
- Source: NBC Bay Area — https://nbcbayarea.com/news/national-international/trump-increased-investments-drugmakers-benefit-medicare-exemptions-democrats/4159026
- Published: 2026-10-16T13:33:49+00:00
- Read time: 1 min
- Topics: trump, medicare, drugmakers, stock portfolio, congressional democrats, pharmaceutical companies, medicare exemptions, president, white house, stock market, news, local
## Democrats report Trump's stock growth
Democrats found Trump's pharmaceutical stock holdings grew from $1.7m in 2024 to $56.2m by end of 2025.
## Medicare exemption policy details
Republicans' 2025 tax bill expanded exemptions for medications treating rare diseases from medicare price negotiations.
## Trump's specific stock purchases
Trump bought up to $950,000 in shares on July 1, 2025, the day the Senate passed the bill.
## AbbVie stock acquisition
Trump's portfolio added up to $1 million in AbbVie stock in August 2025 after the bill became law.
## Medicare beneficiaries impact
Medicare recipients could pay up to $5,000 more annually for cancer drugs like Keytruda and Opdivo.
## White House response
White House spokesperson denied any conflict of interest, saying Trump's portfolio is independently managed.
## Recent polling shows public concern
Most Americans believe Trump is profiting from presidency in unethical or illegal ways.
## Key takeaway

Trump's stock holdings in drugmakers that avoid Medicare price negotiations increased to $56.2m by end of 2025, according to Democratic report.